The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Open accessAbstract
Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two academic institutions and identified 27 patients in whom this developed, or an incidence of 0.9%. The patients had a variety of solid-organ cancers, but all had received either anti–PD-1 or anti–PD-L1 antibodies. Diabetes presented with ketoacidosis in 59%, and 42% had evidence of pancreatitis in the peridiagnosis period. Forty percent had at least one positive autoantibody and 21% had two or more. There was a predominance of HLA-DR4, which was present in 76% of patients. Other immune adverse events were seen in 70%, and endocrine adverse events in 44%. We conclude that autoimmune, insulin-dependent diabetes occurs in close to 1% of patients treated with anti–PD-1 or –PD-L1 CPIs. This syndrome has similarities and differences compared with classic type 1 diabetes. The dominance of HLA-DR4 suggests an opportunity to identify those at highest risk of these complications and to discover insights into the mechanisms of this adverse event.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“To date, the majority of immune checkpoint inhibitor -related cases of type 1 diabetes occur in people with high-risk HLA-DR4 (present in 76% of individuals), whereas other high-risk HLA alleles are not more common than those in the general population (67).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“This immune-related adverse event occurs in just under 1% of checkpoint inhibitor -treated individuals but most commonly occurs with agents that block the programmed cell death protein 1/programmed cell death ligand 1 pathway alone or in combination with other checkpoint inhibitors (67).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“This immune-related adverse event occurs in just under 1% of checkpoint inhibitortreated individuals but most commonly occurs with agents that block the programmed cell death protein 1/programmed cell death ligand 1 pathway alone or in combination with other checkpoint inhibitors (66).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“A new and emerging issue is the development of profound insulin deficiency associated with the use of immune check-point inhibitors, which may present with hyperglycemia and diabetic ketoacidosis (DKA) (4).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is still unclear if steroid-sparing regimens decrease the risk of PTDM with studies showing mixed results.1591–1595”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1593]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Self-citationLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. N. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,455
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,220
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J., Salama, A. D., Chitnis, T., Smith, R. N., Yagita∥, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 817
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Alzenaidi, 2017, Autoimmune diabetes presented with diabetic ketoacidosis induced by immunotherapy in an adult with melanoma, J La State Med Soc, 169, 49
Cited by
Sorted by citations
Items 201–300 of 594
Porntharukchareon, T., Tontivuthikul, B., Sintawichai, N., & Srichomkwun, P. (2020) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02502-w · Cited by 22
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art
on behalf of the Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers, Butterfield, L. H., Disis, M. L., Fox, B. A., Kaufman, D. R., Khleif, S. N., & Wang, E. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0453-4 · Cited by 21
Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
Zhang, L., & Lu, Y. (2021) · Asia-Pacific Journal of Oncology Nursing · doi:10.4103/apjon.apjon-2129 · Cited by 21
Spiliopoulou, P., van Rensburg, H. J. J., Avery, L. M., Kulasingam, V., Razak, A. R. A., Bedard, P. L., Hansen, A. R., Chruscinski, A. J., Wang, B., Kulikova, M., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-022-05548-4 · Cited by 21
Self-citationMiao, Y., Quan, W., Tang, X., Shi, W., Li, Q., Li, R. J., Wang, J., Gan, J., Dong, X., Liang, H., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.89376 · Cited by 23
Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event
Yılmaz, M. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219841116 · Cited by 21
Clinical burden of immune checkpoint inhibitor-induced pneumonitis
Sakamoto, K., Fukihara, J., Morise, M., & Hashimoto, N. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.05.008 · Cited by 21
Zhao, Y., & Wucherpfennig, K. W. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3296 · Cited by 22
Qiu, J., Luo, S., Yin, W., Guo, K., Xiang, Y., Li, X., Liu, Z., & Zhou, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968798 · Cited by 20
Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center
Jeun, R., Iyer, P. C., Best, C. J., Lavis, V. R., Varghese, J. M., Yedururi, S., Brady, V., Oliva, I. C. G., Dadu, R., Milton, D. R., et al. (2023) · Immunotherapy · doi:10.2217/imt-2021-0316 · Cited by 20
Endocrinopathies Associated With Immune Checkpoint Inhibitor Use
Kotwal, A., Kennedy, R., Kikani, N. J., Thosani, S., Goldner, W. S., & Shariff, A. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.023 · Cited by 20
Lo, Y., Price, C. C., Blenman, K., Patil, P., Zhang, X., & Robert, M. E. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa217 · Cited by 22
Lin, A., Zheng, K., Jiang, A., Huang, X., Wang, Q., Hajdú, A., Li, Z., Zhang, J., & Luo, P. (2025) · Med Research · doi:10.1002/mdr2.70019 · Cited by 19
Wang, S., Peng, D., Zhu, H. S., Min, W., Xue, M., Wu, R., Shao, Y., Pan, L., & Zhu, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1053370 · Cited by 19
Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment
Mulla, K., Farag, S., Moore, B., Matharu, S. S., Young, K., Larkin, J., Popat, S., & Morganstein, D. L. (2023) · Diabetic Medicine · doi:10.1111/dme.15053 · Cited by 19
Zhang, Z., Sharma, R., Hamad, L., Riebandt, G., & Attwood, K. M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110776 · Cited by 19
Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy
Townsend, M. J., Liu, M., Giobbie‐Hurder, A., Sack, J., LeBoeuf, N. R., Hodi, F. S., McNabb-Baltar, J. Y., & Grover, S. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7034 · Cited by 19
Al‐Taie, A., & Sheta, N. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.10.016 · Cited by 19
Basek, A., Jakubiak, G. K., Cieślar, G., & Stanek, A. (2023) · Cancers · doi:10.3390/cancers15245786 · Cited by 19
Zieliński, M., Sakowska, J., Iwaszkiewicz‐Grześ, D., Gliwiński, M., Hennig, M., Żalińska, M., Wołoszyn‐Durkiewicz, A., Jaźwińska-Curyłło, A., Kamińska, H., Owczuk, R., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111919 · Cited by 19
Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors
Guo, A.-J., Deng, Q.-Y., Dong, P., Zhou, L., & Shi, L. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i8.1002 · Cited by 19
Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
Sothornwit, J., Phunmanee, A., & Pongchaiyakul, C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00352 · Cited by 19
Alrifai, T., Ali, F. S., Saleem, S., Ruiz, D., Rifai, D., Younas, S., & Qureshi, F. M. (2019) · Case Reports in Oncological Medicine · doi:10.1155/2019/8781347 · Cited by 19
Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
Patel, S., Chin, V. T., & Greenfield, J. R. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0098 · Cited by 19
Immune checkpoint inhibitors and diabetes: Mechanisms and predictors
Youssef, N., Noureldein, M. H., Daoud, G., & Eid, A. A. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.003 · Cited by 19
Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab
Mae, S., Kuriyama, A., & Tachibana, H. (2020) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2020.09.023 · Cited by 19
Tan, B., Chen, M., Guo, Q., Tang, H., Li, Y., Jia, X., Xu, Y., Zhu, L., Wang, M., & Qian, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13990 · Cited by 19
Breaking and restoring immune tolerance to pancreatic beta-cells in type 1 diabetes
Erdem, N., Montero, E., & Roep, B. O. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000646 · Cited by 19
Wang, X., & Jing, J. (2025) · MedComm · doi:10.1002/mco2.70346 · Cited by 21
Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
Profili, N. I., Castelli, R., Gidaro, A., Merella, A., Manetti, R., Palmieri, G., Maioli, M., & Delitala, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155161 · Cited by 18
New Evidence of Exocrine Pancreatopathy in Pre-symptomatic and Symptomatic Type 1 Diabetes
Vecchio, F., Messina, G., Giovenzana, A., & Petrelli, A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1223-5 · Cited by 18
Delasos, L., Bazewicz, C. G., Śliwińska, A., Lopetegui‐Lia, N., & Vredenburgh, J. J. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220943949 · Cited by 18
Shimada, K., Yamamoto, H., Nakatani, E., Kumamaru, H., Nishimura, S., Ichihara, N., Hirahara, N., Mori, K., Kotani, M., Miyachi, Y., et al. (2020) · Endocrine Practice · doi:10.1016/j.eprac.2020.12.009 · Cited by 19
Expert opinion on immunotherapy induced diabetes
Smati, S., Buffier, P., Bouillet, B., Archambeaud, F., Vergès, B. L., & Cariou, B. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.07.006 · Cited by 18
Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer
Khadela, A. D., Chavda, V. P., Postwala, H. I., Ephraim, R., Apostolopoulos, V., & Shah, Y. B. (2023) · Cancers · doi:10.3390/cancers15020543 · Cited by 18
Wei, H., Lai, Y., Lin, G., Lin, C.-W., Chang, Y.-C., Chang, J. W., Liou, M., & Chen, I.-W. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01263-6 · Cited by 17
Fang, Q., Qian, Y., Xie, Z., Zhao, H., Zheng, Y., & Li, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1508512 · Cited by 17
Saito, D., Oikawa, Y., Yano, Y., Ikegami, Y., Satomura, A., Isshiki, M., Kurihara, S., Inoue, I., Noda, M., & Shimada, A. (2019) · Diabetes Care · doi:10.2337/dc18-1673 · Cited by 17
Ohara, N., Kobayashi, M., Ikeda, Y., Hoshi, T., Morita, S., Kanefuji, T., Yagi, K., Suda, T., Takada, T., Hasegawa, G., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.3208-19 · Cited by 17
Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis
Fosci, M., Pigliaru, F., Salcuni, A. S., Ghiani, M., Cherchi, M. V., Calia, M., Loviselli, A., & Velluzzi, F. (2021) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-20-0123 · Cited by 17
Boswell, L., Casals, G., Blanco, J., Jiménez, A., Aya, F., de Hollanda, A., Halperín, I., Arance, A. M., Mora, M., & Hanzu, F. A. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13604 · Cited by 17
Rallis, K. S., Makrakis, D., Ziogas, I. A., & Tsoulfas, G. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i6.448 · Cited by 17
Chye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17
Dökmetaș, M., Muğlu, H., Özcan, E., Bayram, B., Helvacı, K., Kalacı, E., Kahraman, S., Aykan, M. B., Çiçin, İ., Selçukbırıcık, F., et al. (2025) · Medicina · doi:10.3390/medicina61010123 · Cited by 15
Untangling the genetic link between type 1 and type 2 diabetes using functional genomics
Nyaga, D. M., Vickers, M. H., Jefferies, C., Fadason, T., & O'Sullivan, J. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-93346-x · Cited by 16
Shen, M., Chen, D., Zhao, R., Zheng, X., Gu, Y., Yang, T., & Shi, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1213225 · Cited by 16
The Current and Future of Biomarkers of Immune Related Adverse Events
Bracamonte‐Baran, W., & Kim, S. T. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.01.004 · Cited by 16
Townsend, M. J., Benque, I. J., Li, M., & Grover, S. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17980 · Cited by 16
Olivares-Hernández, A., Figuero-Pérez, L., Martin, M. A., Hernández, L. B., Mezquita, L., Tocino, R. V., Cadenas, F. L., López, F. G.-C., Cornejo, R. A. E., & Cruz, J. J. (2021) · Case Reports in Oncological Medicine · doi:10.1155/2021/6631859 · Cited by 16
Silvestris, N., Argentiero, A., Beretta, G. D., Bartolo, P. D., Montagnani, M., Danesi, R., Ferrari, P., D’Oronzo, S., Gori, S., Russo, A. D., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103066 · Cited by 16
The Role of Programmed Death-1 in Type 1 Diabetes
Tucker, C., Dwyer, A. J., Fife, B. T., & Martinov, T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01384-6 · Cited by 16
Endocrine immune-related adverse effects of immune-checkpoint inhibitors
Trevisani, V., Iughetti, L., Lucaccioni, L., & Predieri, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256841 · Cited by 15
Fulminant type 1 diabetes: Focusing on triggering factors
Qiu, J., Yin, W., Wang, R., Luo, S., & Zhou, Z. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3731 · Cited by 15
Harnessing CD8+ T‐cell exhaustion to treat type 1 diabetes
Kwong, C.-T. J., Selck, C., Tahija, K., McAnaney, L. J., Le, D. V., Kay, T. W. H., Thomas, H. E., & Krishnamurthy, B. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12444 · Cited by 15
Muniz, T. P., Araújo, D. V., Savage, K. J. J., Cheng, T., Saha, M., Song, X., Gill, S., Monzon, J. G., Grenier, D., Genta, S., et al. (2021) · Cancers · doi:10.3390/cancers14010089 · Cited by 15
Tryptophan metabolism promotes immune evasion in human pancreatic β cells
Rachdi, L., Zhou, Z., Berthault, C., Lourenço, C., Fouque, A., Domet, T., Armanet, M., You, S., Peakman, M., Mallone, R., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104740 · Cited by 15
Schwartz, S. S., Grant, S. F. A., & Herman, M. E. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1657358 · Cited by 16
Autoimmune complications of cancer immunotherapy
Dhodapkar, K. M. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.08.004 · Cited by 15
Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer
Huang, X., Yang, M., Wang, L., Li, L., & Zhong, X. (2021) · Medicine · doi:10.1097/md.0000000000025795 · Cited by 15
Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer
Li, N., Wang, G., Hou, X., Tai, R., Huang, S., He, Z., Lei, L., Xu, S., & Yang, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108803 · Cited by 15
Xing, X., Zhao, Q. C., Zhou, J., Zhou, R., Liu, Y., Qin, X., Zhang, M., Zhong, Y., Wang, J., Tian, M., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06084-1 · Cited by 14
Liu, Y., Liu, H., Zhao, S., Chen, K., & Jin, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164120 · Cited by 14
Common endocrine system adverse events associated with immune checkpoint inhibitors
Li, Y., Zhao, J., Wang, Y., Xu, Y., Li, R., Zhao, Y., Dong, X., Yao, X., & Li, Y. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.11.005 · Cited by 14
Zatelli, M. C., Faggiano, A., Argentiero, A., Danesi, R., D’Oronzo, S., Fogli, S., Franchina, T., Giorgino, F., Marrano, N., Giuffrida, D., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102734 · Cited by 14
Immunotherapy-Related Acute Kidney Injury
Manohar, S., Jhaveri, K. D., & Perazella, M. A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.07.006 · Cited by 14
Issa, M., Tang, J., Guo, Y., Coss, C. C., Mace, T. A., Bischof, J. J., Phelps, M. A., Presley, C. J., & Owen, D. H. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2094772 · Cited by 14
Hino, C., Nishino, K., Pham, B., Jeon, W. J., Nguyen, M., & Cao, H. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993622 · Cited by 14
Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes
Aktürk, H. K., & Michels, A. W. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000546 · Cited by 15
Stone, S., McPherson, J. P., Kulkarni, R. P., & Young, A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00890-z · Cited by 13
Self-citationBischoff, J., Fries, C., Heer, A., Hoffmann, F., Meyer, C. H., Landsberg, J., & Fenske, W. K. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac036 · Cited by 13
Iwamoto, Y., Kimura, T., Iwamoto, H., Sanada, J., Fushimi, Y., Katakura, Y., Tatsumi, F., Shimoda, M., Nakanishi, S., Mune, T., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1079074 · Cited by 13
Hu, X., Wang, L., Shang, B., Wang, J., Sun, J., Liang, B., Su, L., You, W., & Jiang, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094414 · Cited by 13
Deligiorgi, M. V., & Trafalis, D. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087630 · Cited by 13
Miao, K., & Zhang, L. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.08.002 · Cited by 13
Zhao, P., Zhao, T., Yu, L., Ma, W., Liu, W., & Zhang, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1381250 · Cited by 14
Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon α
Dasgupta, A., Tsay, E., Federman, N. C., Lechner, M. G., & Su, M. A. (2022) · PEDIATRICS · doi:10.1542/peds.2021-053363 · Cited by 13
β cell responses to inflammation
Usmani‐Brown, S., Perdigoto, A. L., Lavoie, N., Clark, P. L., Korah, M. M., Rui, J., Betancur, G., & Herold, K. C. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.013 · Cited by 14
Self-citationEndocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians
Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Immunotherapy · doi:10.2217/imt-2019-0132 · Cited by 13
Yamaguchi, H., Miyoshi, Y., Uehara, Y., Fujii, K., Nagata, S., Obata, Y., Kosugi, M., Hazama, Y., & Yasuda, T. (2020) · Diabetology International · doi:10.1007/s13340-020-00459-1 · Cited by 13
Checkpoint Inhibitor-Induced Autoimmune Diabetes: An Autoinflammatory DiseasePreprint
Quandt, Z., Perdigoto, A. L., Anderson, M. S., & Herold, K. C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041603 · Cited by 13
Self-citationHuman inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency.
Johnson, M. B., Ogishi, M., Domingo‐Vila, C., Franco, E. D., Wakeling, M. N., Imane, Z., Resnick, B., Williams, E., Galão, R. P., Caswell, R. C., et al. (2024) · PubMed Central · doi:10.1084/jem.20231704 · Cited by 16
Self-citationAtezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma
Rahman, W., Conley, A. T., & Silver, K. D. (2020) · BMJ Case Reports · doi:10.1136/bcr-2019-233842 · Cited by 12
Inaba, H., Morita, S., Kosugi, D., Asai, Y., Kaido, Y., Ito, S., Hirobata, T., Inoue, G., Yamamoto, Y., Jinnin, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1165004 · Cited by 12
Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy
Keerty, D., Das, M. K., Johnson, J. E. H., & Haynes, E. (2020) · Cureus · doi:10.7759/cureus.10632 · Cited by 12
Guo, Y., Xu, X., Xu, W., Liao, T., Liang, J., & Yan, J. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13263 · Cited by 12
Champion, B., Chai, S. M., Bhandari, M., & Gunawardena, D. (2022) · Pathology · doi:10.1016/j.pathol.2022.04.010 · Cited by 11
Leverage biomaterials to modulate immunity for type 1 diabetes
Jing, Z., Li, Y., Ma, Y., Zhang, X., Liang, X., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997287 · Cited by 11
Kotwal, A., Perlman, J. E., Goldner, W. S., Marr, A., & Mammen, J. S. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00023 · Cited by 11
Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy
Bastin, M., Mosbah, H., Carlier, A., Boudifa, A., Villemain, A., Hartemann, A., & Andréelli, F. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.04.005 · Cited by 11
Marshall, S., Kizuki, A., Kitaoji, T., Imada, H., Kato, H., Hosoda, M., Ishikawa, M., & Sakura, H. (2020) · Case Reports in Oncology · doi:10.1159/000510044 · Cited by 11
Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces
Deligiorgi, M. V., Liapi, C. A., & Trafalis, D. T. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1869211 · Cited by 11
Etiology and Pathogenesis of Diabetes Mellitus in Children and Adolescents
Yau, M., Maclaren, N. K., & Sperling, M. A. (2021) · Europe PMC (PubMed Central) · Cited by 11
Gómez, P. R. D. V., Piñar-Gutiérrez, A., Guerrero-Vázquez, R., Bellido, V., Morales, C., Sancho-Márquez, M. P., Espejo-García, P., Gros‐Herguido, N., López-Gallardo, G., Martínez‐Brocca, M. A., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4508633 · Cited by 11
Seguí, E., Zamora, C., Barreto, T. D., Padrosa, J., Viladot, M., & Marco‐Hernández, J. (2022) · Diagnostics · doi:10.3390/diagnostics12092116 · Cited by 10
Current landscape and tailored management of immune-related adverse events
Liu, W., Luo, Z., Liu, Y., & Sun, B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1078338 · Cited by 10
Nivolumab-induced diabetes mellitus—a case report with literature review of the treatment options
Daetwyler, E., Zippelius, A., Danioth, S., Donath, M. Y., & Gut, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248919 · Cited by 10
Selck, C., Jhala, G., George, D. J. D., Kwong, C.-T. J., Christensen, M. K., Pappas, E. G., Liu, X., Ge, T., Trivedi, P., Kallies, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2315419121 · Cited by 10
Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review
Lyadova, M. A., & Lyadov, V. K. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.2.200502 · Cited by 10
Park, B. J., Stone, C. A., Dewan, A. K., & Johnson, D. B. (2022) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.12.006 · Cited by 10
Li, M., Wu, C., Liu, Y., Zhang, R., Yang, Q., Shi, Z., Sun, W., & Hu, X. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s353403 · Cited by 10
Metadata
- Authors
- Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., Lee, J., Bluestone, J. A., Anderson, M., & Herold, K. C.
- Affiliations
- Yale University (US)
- University of California, San Francisco (US)
- Corresponding author
- Herold, Kevan C.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-06-24
- Volume
- 67
- Issue
- 8
- Pages
- 1471-1480
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6054443
- OpenAlex
- W2808896902
- Cited by
- 590
- References
- 51
- Citations by year
- 2026: 41 · 2025: 75 · 2024: 76 · 2023: 90 · 2022: 80 · 2021: 92 · 2020: 69 · 2019: 52 · 2018: 14
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK057846, UC4 DK116290)
- Leona M. and Harry B. Helmsley Charitable Trust (2018PG-T1D059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune checkpoint inhibitors, type 1 diabetes, anti-PD-1, PD-L1 inhibitors, immune-related adverse events, ketoacidosis, pancreatitis, autoantibodies, HLA-DR4, solid organ cancer, endocrine adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Insulin Secretion, Animals, Autoimmune Diseases, Diabetes Mellitus, Type 1, Genotype, Humans, Hypoglycemic Agents, Insulin, Isoantibodies, Ketosis, Neoplasms, Pancreas, Pancreatitis, HLA-DR4 Antigen, Models, Immunological, Genetic Predisposition to Disease, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
